Block Listing 6 Monthly Return

Source: RNS
RNS Number : 8285G
Shield Therapeutics PLC
31 March 2022
 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Block Listing 6 Monthly Return

 

Date: 31 March 2022

 

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

Shield Therapeutics Retention Share Plan

Period of return:

From:

30 September 2021

To:

31 March 2022

Balance of unallotted securities under scheme(s) from previous return:

39,794

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

39,794

         

 

Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

Shield Therapeutics plc 2016 Company Share Option Plan

Period of return:

From:

30 September 2021

To:

31 March 2022

Balance of unallotted securities under scheme(s) from previous return:

388,079

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-47,059

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

341,020

         

 

 

 Name of applicant:

SHIELD THERAPEUTICS PLC

 

Name of scheme:

The Shield Therapeutics plc 2016 Long Term Incentive Plan

Period of return:

From:

30 September 2021

To:

31 March 2022

Balance of unallotted securities under scheme(s) from previous return:

24,273

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

24,273

         

 

 

Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

Shield Therapeutics Retention and Performance Share Plan

Period of return:

From:

30 September 2021

To:

31 March 2022

Balance of unallotted securities under scheme(s) from previous return:

3,178,276

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

3,178,276

         

 

Name of contact:

Lucy Huntington-Bailey

Telephone number of contact:

+44 (0) 191 511 8500

 

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Greg Madison, CEO

+44 (0) 191 511 8500

Hans-Peter Rudolf, CFO

 

 

Nominated Adviser and Joint Broker

 

Peel Hunt LLP

 

James Steel/Christopher Golden

+44 (0)20 7418 8900

 

Joint Broker

finnCap Ltd     

Geoff Nash/Alice Lane/George Dollemore                                            

 

 

 

+44 (0)20 7220 0500

 

 

Financial PR & IR Advisor

 

Walbrook PR (UK Advisor)

 

Paul McManus/Lianne Applegarth/Alice Woodings

 

Investor Contact (US Advisor)

+44 (0)20 7933 8780 or shield@walbrookpr.com

LifeSci Advisors, LLC

John Mullaly

 

 

+1 617 429 3548 or jmullaly@lifesciadvisors.com

 

 

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.

 

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRJBMITMTJJBLT